Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pneuma Respiratory has developed a proprietary digital breath-actuated inhaler platform capable of delivering both small molecules and large-molecule biologics as sub-micron aerosols. The technology is being applied to reduced-risk nicotine delivery, COPD, and NSCLC. Early studies show high lung penetration (>90% respirable fraction), precise dosing, and preservation of biologic drug structure during delivery. Clinical trials were planned as of 2019; current clinical results are not publicly detailed but the company is actively partnering for global commercialization.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pneuma Respiratory.